3/18
07:54 am
rare
Rating for RARE
Low
Report
Rating for RARE
2/27
01:13 pm
rare
Rating for RARE
Low
Report
Rating for RARE
2/27
10:17 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
2/27
09:22 am
rare
Rating for RARE
Medium
Report
Rating for RARE
2/21
09:12 am
rare
Rating for RARE
Low
Report
Rating for RARE
2/16
08:53 am
rare
Rating for RARE
Low
Report
Rating for RARE
2/16
08:53 am
rare
Rating for RARE
Low
Report
Rating for RARE
2/15
09:18 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $114.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $114.00 price target on the stock.
2/15
09:12 am
rare
Rating for RARE
Low
Report
Rating for RARE
1/30
01:39 pm
rare
Rating for RARE
Low
Report
Rating for RARE
1/30
01:39 pm
rare
Rating for RARE
Low
Report
Rating for RARE
1/19
10:11 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $114.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $114.00 price target on the stock.
1/19
09:31 am
rare
Rating for RARE
Medium
Report
Rating for RARE